-
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market
-
GT Biopharma to Present at Roth Capital Partners 30th Annual Conference
-
GT Biopharma Announces $7.1 Million Convertible Debt Financing
-
GT Biopharma Announces $7.1 Million Convertible Debt Financing
-
GT Biopharma Announces $7.1 Million Convertible Debt Financing

